Abstract
Acute myocardial infarction (AMI) constitutes the major cause of death in most nations and death rates and morbidity remain substantial in the years thereafter. Inflammation is a hallmark throughout the distinct stages of atherosclerotic lesion formation preceding AMI as well as at the time of plaque rupture and during the post-infarct repair phase. Epidemiological, genetic, clinical and experimental evidence converges on inflammation as a pivotal factor in disease progression and exacerbation. Harnessing its harmful consequences constitutes an attractive therapeutic approach to address this unmet medical need. Components of the innate and adaptive immune system with the characteristic cytokines interleukin-1 and tumor necrosis factor-α, respectively exert prominent functions in atherogenesis and post-infarct remodeling. Leukocyte subsets of the monocyte/macrophage and CD4+ T lymphocyte cell lineage interacting with a vast array of cells comprising platelets, neutrophils, dendritic cells, mast cells, vascular smooth muscle cells and fibroblasts orchestrate the inflammatory pathophysiology underlying plaque progression in the vasculature and fibrotic repair of the infarct. This pathophysiology is amenable to modification by drugs targeting cell proliferation, cell migration, osteogenic/fibrous turnover of the extracellular matrix ranging from antimetabolites, glucocorticoids, specific cytokine and leukotriene antagonists to classic immunosuppressive agents and vaccines directed specifically at certain disease-relevant antigens. Based on published data on clinical safety and clinical/experimental efficacy in inhibiting disease progression this review covers recent advances in this field and aims to propose candidate drugs for future clinical trials.
Keywords: Coronary artery disease, myocardial infarction, atherosclerosis, inflammation, immune system, drugs, pharmaceutics, pharmaceutics, Acute myocardial infarction (AMI), interleukin-1, tumor necrosis factor-α
Current Pharmaceutical Design
Title:Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Volume: 18 Issue: 28
Author(s): Roland Klingenberg and Thomas F. Luscher
Affiliation:
Keywords: Coronary artery disease, myocardial infarction, atherosclerosis, inflammation, immune system, drugs, pharmaceutics, pharmaceutics, Acute myocardial infarction (AMI), interleukin-1, tumor necrosis factor-α
Abstract: Acute myocardial infarction (AMI) constitutes the major cause of death in most nations and death rates and morbidity remain substantial in the years thereafter. Inflammation is a hallmark throughout the distinct stages of atherosclerotic lesion formation preceding AMI as well as at the time of plaque rupture and during the post-infarct repair phase. Epidemiological, genetic, clinical and experimental evidence converges on inflammation as a pivotal factor in disease progression and exacerbation. Harnessing its harmful consequences constitutes an attractive therapeutic approach to address this unmet medical need. Components of the innate and adaptive immune system with the characteristic cytokines interleukin-1 and tumor necrosis factor-α, respectively exert prominent functions in atherogenesis and post-infarct remodeling. Leukocyte subsets of the monocyte/macrophage and CD4+ T lymphocyte cell lineage interacting with a vast array of cells comprising platelets, neutrophils, dendritic cells, mast cells, vascular smooth muscle cells and fibroblasts orchestrate the inflammatory pathophysiology underlying plaque progression in the vasculature and fibrotic repair of the infarct. This pathophysiology is amenable to modification by drugs targeting cell proliferation, cell migration, osteogenic/fibrous turnover of the extracellular matrix ranging from antimetabolites, glucocorticoids, specific cytokine and leukotriene antagonists to classic immunosuppressive agents and vaccines directed specifically at certain disease-relevant antigens. Based on published data on clinical safety and clinical/experimental efficacy in inhibiting disease progression this review covers recent advances in this field and aims to propose candidate drugs for future clinical trials.
Export Options
About this article
Cite this article as:
Klingenberg Roland and F. Luscher Thomas, Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?, Current Pharmaceutical Design 2012; 18 (28) . https://dx.doi.org/10.2174/138161212802481219
DOI https://dx.doi.org/10.2174/138161212802481219 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia
Current Psychiatry Reviews Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Therapeutic Angiogenesis in Ischemic Heart Disease: Gene or Recombinant Vascular Growth Factor Protein Therapy?
Current Gene Therapy HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview
Current Drug Metabolism Acute Severe Arterial Hypertension: Therapeutic Options
Current Drug Targets Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Current Pharmaceutical Biotechnology Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited
Current Medicinal Chemistry The Potential Role of Antioxidants in Metabolic Syndrome
Current Pharmaceutical Design Prevalence of Congenital Heart Disease among Children in Khorramabad (West of Iran)
Cardiovascular & Hematological Disorders-Drug Targets Chemometric Modeling of 5-Phenylthiophenecarboxylic Acid Derivatives as Anti-Rheumatic Agents
Current Computer-Aided Drug Design Effects of Dietary Coconut Oil on Erucic Acid Rich Rapeseed Oil-induced Changes of Blood Serum Lipids in Rats
Current Nutrition & Food Science Are Retinoids a Promise for Alzheimer’s Disease Management?
Current Medicinal Chemistry Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews Recent Advances in Fe-MOF Compositions for Biomedical Applications
Current Medicinal Chemistry Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Air Pollution and Lung Cancer
Current Respiratory Medicine Reviews Epidemiological Evidence Associating Secondhand Smoke Exposure with Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) Can't Always Get What you Want? Try an Indirect Route you Just Might Get What you Need: A Study on Access to Genetic Data by Canadian Life Insurers
Current Pharmacogenomics and Personalized Medicine